Drugs / Fispemifene
Fispemifene
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02443090 | May → Oct 2015 | erectile dysfunction, hypogonadism, sexual disorder | NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | Unknown | No outcome recorded |
| Phase 2 | NCT01061970 | Jan → Oct 2007 | chronic obstructive pulmonary disease, hypogonadism, male | QuatRx Pharmaceuticals Company | Completed | No outcome recorded |
| Phase 2 | NCT00415571 | Dec 2006 → Aug 2008 | erectile dysfunction, hypogonadism | QuatRx Pharmaceuticals Company | Completed | No outcome recorded |
| Phase 2 | NCT00290134 | Feb 2006 → Oct 2007 | hypogonadism | QuatRx Pharmaceuticals Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fispemifene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00290134 ↗ |
| Known as | Fispemifeno | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107341 ↗ |
| Known as | HM-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107341 ↗ |
| Known as | HM-101a | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107341 ↗ |
| Modality | Small molecule | — CHEMBL2107341 ↗ |
| Route | Oral | “Daily Oral Doses” NCT00290134 ↗ |